Atrium Therapeutics, Inc. Common Stock Wells Fargo 21st Annual Healthcare Conference

Good morning, Yanan. Thank you so much for having us. It is really nice to be back. Great to see you. Great.

Thank you. Yeah, of course.

I will get started, and then maybe Brendan, I will hand it over to you to talk a little bit about the formation. Atrium, we just passed our six-month mark. We were formed out of Avidity, when the Avidity, Novartis transaction happened late last year. Our focus and our vision is to profoundly improve patients' lives by pioneering RNA therapeutics for the heart. It is an incredible opportunity to really take the RNA delivery platform that we had had the ability to work on at Avidity and bring that to cardiac patients. As you think about how Atrium was set up, we were set up with funding, which Brendan can talk a little bit about as well, but more importantly, we have four programs that we are able to work on.

The first two, we have our first one for PRKAG2 syndrome, which is going to be entering the clinic shortly here. We are in the final processes of just getting our phase I up and running to initiate our first patient. We have a second program in phospholamban cardiomyopathy, beyond that, we have two additional programs also for genetic cardiomyopathies. When you think about the cardiac space, there have been a tremendous amount of therapies for cardiovascular patients, but the rare genetic cardiomyopathy community has really been left behind, most of those patients today are treated with symptomatic management. For Atrium, this is an incredible opportunity to really pioneer that work, to really bring precision therapies to patients and actually target the root cause of their diseases.

Brendan. Yeah, happy to. Yanan, as you think about the impetus for the spin-out transaction with Atrium, you will recall that Avidity's portfolio consisted of both late-stage neuromuscular assets as well as earlier-stage precision cardio programs.

I think with the spin-out of Atrium, it allows us to put our team's full focus in the precision cardio space, as well as continuing to progress our existing collaborations with Eli Lilly and BMS, which were assumed in the spin-out. As Kath mentioned, with our lead programs in PRKAG2 syndrome and PLN cardiomyopathy, these are diseases that have no approved therapies for their underlying cause of their diseases, we are going to be paving new pathways along the way, which as a smaller biotech, we are particularly well-suited for.

Absolutely. When you think about AOCs, what we are doing with them is we are using a monoclonal antibody to the transferrin receptor. What we are doing is linking that to an siRNA. Why that is really fantastic for the cardiovascular space is because while there have been a number of targets in the heart for a long time, they have been targets that you really could not access. The AOC platform really allows us to deliver, for example, an siRNA to PRKAG2 to the heart. AOCs in particular and the transferrin receptor, we really get a tremendous amount of— There is a lot of transferrin receptor in the heart. Because of that, our AOCs really have a lot of delivery there.

You will even see, as we talk later about our dosing and our Phase I/II study, that we do not have to use as high of doses, things like that, because of the fact that we get so much more into the heart. It really is this kind of twofold piece of the heart itself, it really has a lot of transferrin. It is naturally expressing it, so we are utilizing that natural biology to get in there. In addition, we can actually target the underlying cause of the disease and really deliver that siRNA directly to where we think will have an impact.